United Therapeutics Corporation
United Therapeutics Corporation/ US91307C1027 /
UTHR
|
16.05.2024 22:00:00
|
Zm.
-0,4700
|
Wolumen |
Bid22:27:17 |
Ask22:27:17 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
|
272,2200USD
|
-0,17%
|
463 902
Obrót: 70,72 mln |
270,0100Wolumen Bid: 200 |
274,9900Wolumen Ask: 200 |
12,07 mldUSD |
- |
12,94 |
Opis działalności
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.
Zarząd & Rada nadzorcza
| CEO |
| Dr. Martine A. Rothblatt |
| Zarząd |
| James C. Edgemond, Michael Benkowitz, Paul A. Mahon |
| Rada nadzorcza |
| Dr. Martine A. Rothblatt, Christopher Causey, Christopher Patusky, Dr. Judy D. Olian, Dr. Katherine J. Klein, Linda Maxwell, M.D., Louis Sullivan, Nilda Mesa, Prof. Raymond Dwek, Ray Kurzweil, Richard Giltner, Tommy G. Thompson |
Dane firmy
| Nazwa: |
United Therapeutics Corporation |
| Adres: |
1040 Spring Street,Silver Spring, Maryland 20910, USA |
| Telefon: |
+1-301-608-9292 |
| Fax: |
+1-301-608-9291 |
| E-mail: |
-
|
| Internet: |
is.gd/1hUSaA |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
Biotechnologia |
| Koniec roku finansowego: |
31.12 |
| Free float: |
61,80% |
| Data IPO: |
- |
Relacje inwestorskie
| Nazwa: |
- |
| Telefon: |
- |
| Fax: |
- |
| E-mail: |
ir@unither.com
|
Główni akcjonariusze
| Freefloat |
|
61,80% |
| BlackRock, Inc |
|
9,60% |
| The Vanguard Group |
|
8,90% |
| Renaissance Technologies LLC |
|
8,10% |
| Avoro Capital Advisors LLC |
|
6,40% |
| FMR, LLC |
|
5,20% |
